ArticleInvestigational new drugs2022

KAT2B is an immune infiltration-associated biomarker predicting prognosis and response to immunotherapy in non-small cell lung cancer.

Xue Zhou et al.PubMed ↗Publisher ↗

No numbers read from the abstract.